Back to companies

Mitsubishi Tanabe Pharma Corp: Premium Databases

Mitsubishi Tanabe Pharma Corp Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Mitsubishi Tanabe Pharma Corp Insights data

Headline Published Journalists
Showing 3 of 14+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 08 Dec 2021 Lorem
Mitsubishi Tanabe Pharma’s ND0612 holds Phase III success uncertainty but its noninvasive delivery draws rescue therapy interest in Parkinson’s disease, even over oral approaches, experts say 20 Nov 2019 Shuan Sim
Akebia's vadadustat in CKD with anemia will focus on secondary endpoint values for future payer discussions- CEO 15 Jan 2018 Jennifer C. Smith-Parker
NeuroSense Therapeutics seeks CRO to help run Phase II ALS trial initiating in 3Q18 – CEO 22 Nov 2017 Christina Hwang


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer